Loading...
By Joe Elia
Edited by Jaye Elizabeth Hefner, MD
For extended prophylaxis against venous thromboembolism after hip or knee arthroplasty, aspirin performed as well as rivaroxaban in a double-blind trial.
EPCAT II investigators randomized some 3500 patients undergoing arthroplasty. All received an initial 5 days' postoperative treatment with rivaroxaban. Then, knee-replacement patients were randomized to an added 9 days' prophylaxis with either low-dose aspirin or rivaroxaban; hip replacements were randomized to an added 30 days.
The incidence of symptomatic venous thromboembolism by 90 days (the primary effectiveness outcome) was similar in the two groups; bleeding episodes (the primary safety endpoint) were also similar.
Writing in the New England Journal of Medicine, an editorialist calls the findings likely practice-changing. He concludes that the trial "has established a prophylaxis regimen against which all strategies to prevent venous thromboembolism after joint replacement will be compared."
Comment
LINK(S):
NEJM article (Free abstract)
NEJM editorial (Subscription required)
Background: Physician's First Watch coverage of earlier study comparing aspirin with dalteparin after arthroplasty (Free)